Hledání článků
Filtry
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).
J Hypertens 2023;41:1874–2071.
Morello W, Baskin E, Jankauskiene A, et al; PREDICT Study Group. Antibiotic Prophylaxis in Infants with Grade III, IV, or V Vesicoureteral Reflux.
N Engl J Med 2023;389:987–997.
van Luijk F, Gansevoort RT, Blokzijl H, et al. Multidisciplinary management of chronic refractory pain in autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant 2023;38:618–629.
Blankestijn PJ, Vernooij RWM, Hockham C, et al.; for the CONVINCE Scientific Committee Investigators. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure.
N Engl J Med 2023 Jun 16. doi: 10.1056/NEJMoa2304820. Online ahead of print.
Hughes DA, Bichet DG, Giugliani R, et al. Long‑term multisystemic efficacy of migalastat on Fabry‑associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet 2023;60:722–731.
Jerman A, Andonova M, Persic V, et al. Extracorporal Removal of Myoglobin in Patients with Rhabdomyolysis and Acute Kidney Injury: Comparison of High and Medium Cut‑Off Membrane and an Adsorber Cardridge. Blood Purif 2022;51:907–911.
Anazodo UC, Wong DY, Théberge Jean, et al. Hemodialysis‑Related Acute Brain Injury Demonstrated by Application of Intradialytic Magnetic Resonance Imaging and Spectroscopy. J Am Soc Nephrol 2023;34:1090–1104.
Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension. Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023 Jun 21. doi: 10.1097/HJH.0000000000003480. Epub ahead of print.
Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med 2023;389:228–238.
Hayes W, Sas DJ, Magen D, et al. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12‑month analysis of the phase 3 ILLUMINATE‑B trial. Pediatr Nephrol 2023;38:1075–1086.